Kexing Biopharm Past Earnings Performance
Past criteria checks 0/6
Kexing Biopharm's earnings have been declining at an average annual rate of -73.6%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 2.8% per year.
Key information
-73.6%
Earnings growth rate
-75.9%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 2.8% |
| Return on equity | -7.6% |
| Net Margin | -8.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
There's No Escaping Kexing Biopharm Co., Ltd.'s (SHSE:688136) Muted Revenues Despite A 36% Share Price Rise
Oct 08
Kexing Biopharm Co., Ltd.'s (SHSE:688136) Share Price Boosted 36% But Its Business Prospects Need A Lift Too
May 21Shandong Kexing Bioproducts Co,.Ltd (SHSE:688136) Held Back By Insufficient Growth Even After Shares Climb 25%
Mar 08Revenue & Expenses Breakdown
How Kexing Biopharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,328 | -119 | 691 | 290 |
| 30 Jun 24 | 1,370 | -131 | 730 | 301 |
| 31 Mar 24 | 1,297 | -169 | 779 | 331 |
| 31 Dec 23 | 1,259 | -190 | 773 | 345 |
| 30 Sep 23 | 1,341 | -87 | 845 | 238 |
| 30 Jun 23 | 1,335 | -141 | 935 | 238 |
| 31 Mar 23 | 1,369 | -128 | 964 | 212 |
| 31 Dec 22 | 1,316 | -90 | 914 | 193 |
| 30 Sep 22 | 1,333 | -37 | 946 | 171 |
| 30 Jun 22 | 1,319 | 39 | 876 | 162 |
| 31 Mar 22 | 1,278 | 79 | 830 | 138 |
| 31 Dec 21 | 1,285 | 96 | 845 | 123 |
| 30 Sep 21 | 1,225 | 97 | 767 | 91 |
| 30 Jun 21 | 1,250 | 105 | 785 | 70 |
| 31 Mar 21 | 1,152 | 100 | 720 | 63 |
| 31 Dec 20 | 1,220 | 139 | 729 | 58 |
| 30 Sep 20 | 1,220 | 158 | 725 | 55 |
| 31 Dec 19 | 1,191 | 160 | 718 | 45 |
| 31 Dec 18 | 891 | 94 | 547 | 42 |
| 31 Dec 17 | 616 | 59 | 351 | 31 |
Quality Earnings: 688136 is currently unprofitable.
Growing Profit Margin: 688136 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688136 is unprofitable, and losses have increased over the past 5 years at a rate of 73.6% per year.
Accelerating Growth: Unable to compare 688136's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688136 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).
Return on Equity
High ROE: 688136 has a negative Return on Equity (-7.63%), as it is currently unprofitable.